Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
Identifieur interne : 000266 ( PubMed/Curation ); précédent : 000265; suivant : 000267Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
Auteurs : Sébastien D S. Pion [France] ; Cédric B. Chesnais [France] ; Gary J. Weil [États-Unis] ; Peter U. Fischer [États-Unis] ; François Missamou [République du Congo] ; Michel Boussinesq [République du Congo]Source :
- The Lancet. Infectious diseases [ 1474-4457 ] ; 2017.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Albendazole (administration et posologie), Albendazole (usage thérapeutique), Animaux, Antihelminthiques (administration et posologie), Antihelminthiques (usage thérapeutique), Antiparasitaires (effets indésirables), Antiparasitaires (usage thérapeutique), Enfant, Facteurs temps, Femelle, Filariose lymphatique (parasitologie), Filariose lymphatique (traitement médicamenteux), Fèces (parasitologie), Helminthiase (parasitologie), Helminthiase (traitement médicamenteux), Humains, Ivermectine (effets indésirables), Ivermectine (usage thérapeutique), Loase (), Mâle, Sol (parasitologie).
- MESH :
- administration et posologie : Albendazole, Antihelminthiques.
- effets indésirables : Antiparasitaires, Ivermectine.
- parasitologie : Filariose lymphatique, Fèces, Helminthiase, Sol.
- traitement médicamenteux : Filariose lymphatique, Helminthiase.
- usage thérapeutique : Albendazole, Antihelminthiques, Antiparasitaires, Ivermectine.
- Adolescent, Adulte, Animaux, Enfant, Facteurs temps, Femelle, Humains, Loase, Mâle.
English descriptors
- KwdEn :
- Adolescent, Adult, Albendazole (administration & dosage), Albendazole (therapeutic use), Animals, Anthelmintics (administration & dosage), Anthelmintics (therapeutic use), Antiparasitic Agents (adverse effects), Antiparasitic Agents (therapeutic use), Child, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (parasitology), Feces (parasitology), Female, Helminthiasis (drug therapy), Helminthiasis (parasitology), Humans, Ivermectin (adverse effects), Ivermectin (therapeutic use), Loiasis (complications), Male, Soil (parasitology), Time Factors.
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics.
- chemical , adverse effects : Antiparasitic Agents, Ivermectin.
- chemical , parasitology : Soil.
- chemical , therapeutic use : Albendazole, Anthelmintics, Antiparasitic Agents, Ivermectin.
- complications : Loiasis.
- drug therapy : Elephantiasis, Filarial, Helminthiasis.
- parasitology : Elephantiasis, Filarial, Feces, Helminthiasis.
- Adolescent, Adult, Animals, Child, Female, Humans, Male, Time Factors.
Abstract
The standard treatment strategy of mass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because of the risk of serious adverse events in people with high Loa loa microfilaraemia. Thus, alternative strategies are needed. We investigated one such alternative strategy for mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in Republic of the Congo.
DOI: 10.1016/S1473-3099(17)30175-5
PubMed: 28372977
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000266
Links to Exploration step
pubmed:28372977Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.</title><author><name sortKey="Pion, Sebastien D S" sort="Pion, Sebastien D S" uniqKey="Pion S" first="Sébastien D S" last="Pion">Sébastien D S. Pion</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France. Electronic address: sebastien.pion@ird.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Chesnais, Cedric B" sort="Chesnais, Cedric B" uniqKey="Chesnais C" first="Cédric B" last="Chesnais">Cédric B. Chesnais</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea></affiliation></author><author><name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U" last="Fischer">Peter U. Fischer</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea></affiliation></author><author><name sortKey="Missamou, Francois" sort="Missamou, Francois" uniqKey="Missamou F" first="François" last="Missamou">François Missamou</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea></affiliation></author><author><name sortKey="Boussinesq, Michel" sort="Boussinesq, Michel" uniqKey="Boussinesq M" first="Michel" last="Boussinesq">Michel Boussinesq</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28372977</idno><idno type="pmid">28372977</idno><idno type="doi">10.1016/S1473-3099(17)30175-5</idno><idno type="wicri:Area/PubMed/Corpus">000266</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000266</idno><idno type="wicri:Area/PubMed/Curation">000266</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000266</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.</title><author><name sortKey="Pion, Sebastien D S" sort="Pion, Sebastien D S" uniqKey="Pion S" first="Sébastien D S" last="Pion">Sébastien D S. Pion</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France. Electronic address: sebastien.pion@ird.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Chesnais, Cedric B" sort="Chesnais, Cedric B" uniqKey="Chesnais C" first="Cédric B" last="Chesnais">Cédric B. Chesnais</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea></affiliation></author><author><name sortKey="Fischer, Peter U" sort="Fischer, Peter U" uniqKey="Fischer P" first="Peter U" last="Fischer">Peter U. Fischer</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO</wicri:regionArea></affiliation></author><author><name sortKey="Missamou, Francois" sort="Missamou, Francois" uniqKey="Missamou F" first="François" last="Missamou">François Missamou</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea></affiliation></author><author><name sortKey="Boussinesq, Michel" sort="Boussinesq, Michel" uniqKey="Boussinesq M" first="Michel" last="Boussinesq">Michel Boussinesq</name><affiliation wicri:level="1"><nlm:affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</nlm:affiliation><country xml:lang="fr">République du Congo</country><wicri:regionArea>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Lancet. Infectious diseases</title><idno type="eISSN">1474-4457</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Albendazole (administration & dosage)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Anthelmintics (administration & dosage)</term><term>Anthelmintics (therapeutic use)</term><term>Antiparasitic Agents (adverse effects)</term><term>Antiparasitic Agents (therapeutic use)</term><term>Child</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Feces (parasitology)</term><term>Female</term><term>Helminthiasis (drug therapy)</term><term>Helminthiasis (parasitology)</term><term>Humans</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (therapeutic use)</term><term>Loiasis (complications)</term><term>Male</term><term>Soil (parasitology)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Albendazole (administration et posologie)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Antihelminthiques (administration et posologie)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Antiparasitaires (effets indésirables)</term><term>Antiparasitaires (usage thérapeutique)</term><term>Enfant</term><term>Facteurs temps</term><term>Femelle</term><term>Filariose lymphatique (parasitologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Fèces (parasitologie)</term><term>Helminthiase (parasitologie)</term><term>Helminthiase (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (usage thérapeutique)</term><term>Loase ()</term><term>Mâle</term><term>Sol (parasitologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="parasitology" xml:lang="en"><term>Soil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Loiasis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Helminthiasis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiparasitaires</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Fèces</term><term>Helminthiase</term><term>Sol</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Feces</term><term>Helminthiasis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Helminthiase</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Antiparasitaires</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Animaux</term><term>Enfant</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Loase</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The standard treatment strategy of mass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because of the risk of serious adverse events in people with high Loa loa microfilaraemia. Thus, alternative strategies are needed. We investigated one such alternative strategy for mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in Republic of the Congo.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28372977</PMID><DateCreated><Year>2017</Year><Month>04</Month><Day>04</Day></DateCreated><DateCompleted><Year>2017</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.</ArticleTitle><Pagination><MedlinePgn>763-769</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(17)30175-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(17)30175-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The standard treatment strategy of mass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because of the risk of serious adverse events in people with high Loa loa microfilaraemia. Thus, alternative strategies are needed. We investigated one such alternative strategy for mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in Republic of the Congo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In 2012, we started a 3 year community trial of biannual mass administration of albendazole in a village in Republic of the Congo. All volunteering inhabitants aged 2 years or older were offered albendazole (400 mg) every 6 months. Infection with Wuchereria bancrofti was diagnosed with a rapid card immunochromatographic test for antigenaemia. People with antigenaemia were tested for microfilaraemia by night blood smears. Individuals were also tested for soil-transmitted helminth infections (ie, hookworm, Ascaris lumbricoides, Trichuris trichiura) with the Kato-Katz method. Assessment surveys were done at 12, 24, and 36 months. The main outcome measure was change in infection rates from baseline to year 3.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Therapeutic coverage was more than 80% in all six rounds of mass administration of albendazole. Between 2012 and 2015, W bancrofti antigenaemia and microfilaraemia rates in the community fell significantly, from 17·3% (95% CI 14·7-20·0) to 4·7% (3·3-6·6; p<0·0001) and from 5·3% (3·9-7·1) to 0·3% (0·1-1·2; p<0·0001), respectively. The geometric mean microfilaria count in microfilaraemic people fell from 199·4 (120·4-330·5) per mL in 2012 to 39·1 (95% CIs not computed) per mL in 2015 (p=0·0095). Hookworm infection was undetectable after 1 year. Between 2012 and 2015, the number of A lumbricoides eggs expelled per g of faeces fell from 9844·6 (8209·0-11 480·0) to 724·4 (340·7-1114·2; p<0·0001), and of T trichiura eggs from 1107·4 (878·5-1336·3) to 366·0 (255·7-476·2; p<0·0001).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings strongly support WHO's provisional strategy of biannual mass administration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemic and ivermectin cannot be safely mass administered.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Bill & Melinda Gates Foundation.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pion</LastName><ForeName>Sébastien D S</ForeName><Initials>SDS</Initials><AffiliationInfo><Affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France. Electronic address: sebastien.pion@ird.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesnais</LastName><ForeName>Cédric B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weil</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Peter U</ForeName><Initials>PU</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Missamou</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boussinesq</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Programme National de Lutte contre l'Onchocercose, Direction de l'Epidémiologie et de la Lutte contre la Maladie, Ministère de la Santé et de la Population, Brazzaville, Republic of the Congo.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000977">Antiparasitic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012987">Soil</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000977" MajorTopicYN="N">Antiparasitic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006373" MajorTopicYN="N">Helminthiasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008118" MajorTopicYN="N">Loiasis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012987" MajorTopicYN="N">Soil</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="Y">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>02</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28372977</ArticleId><ArticleId IdType="pii">S1473-3099(17)30175-5</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(17)30175-5</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000266 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000266 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28372977
|texte= Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28372977" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |